MRFR Year End Sale
Renal Cancer Drugs Market Research Report – Forecast to 2030

Renal Cancer Drugs Market Research Report, by Therapeutic Class (Targeted Therapy and ImmunoTherapy), Pharmacologic Class (Angiogenesis Inhibitors), Type (Clear Cell, Papillary, Oncocytic), End-Users (Hospitals &clinics) - Forecast Till 2030

ID: MRFR/Pharma/5004-HCR | | Region: Global | 100 Pages         

Renal Cancer Drug Market Speak to Analyst Request a Free Sample

Renal Cancer Drugs Market Scenario


The Renal Cancer Drugs market is expected to reach USD 6.4 Billion by 2030 at 5.50% CAGR during the forecast period 2022-2030. Renal cancer also called as kidney cancer or hypernephroma. Renal cancer is a disease in which kidney cells become malignant, the cells start proliferating out of control and start forming a tumor. Principal locations for kidney cancer are renal tube and renal pelvis. It is observed both in males and females between the age group of 50 to 80 years. The key factors responsible for influencing renal cancer drugs market are increasing use of tobacco, smoking, and increasing alcohol consumption which can also lead to cause renal cancer. Other factors of renal cancer drugs market which support to cause renal cancer are obesity and mutation in von Hippel-Lindau (VHL) gene. According to the World Cancer Research Fund, 2018 database has estimated kidney cancer is the ninth most commonly occurring cancer in men and 14th most commonly occurring cancer in women. According to the American Cancer Society in 2018, 63,340 new cases of kidney cancer are estimated in the US This is expected to provide favorable backgrounds for the renal cancer drugs market growth during the forecast period.


However, factors such as the high cost of expensive chemotherapy, increasing preference for generic drugs and side effects associated with drugs are expected to restrict the renal cancer drugs market growth during the forecast period.


Segmentation


The renal cancer drugs market is segmented on the basis of therapeutic class, pharmacologic class, type, and end-user. The renal cancer drugs market, by therapeutic class, is categorized into targeted therapy and immunotherapy. On the basis of pharmacologic class, the market is segmented into angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies and cytokine immunotherapy (IL-2). On the basis of type, the market is segmented into the clear cell, papillary, chromophobe, oncocytic, collecting duct and other. On the basis of end-user, the market is segmented hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers and other.


On the basis of region, the renal cancer drugs market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players


Some of the key players in the global renal cancer drugs market are Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Genentech, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Cipla Limited (India), Active Biotech AB (Sweden), Amgen (US), Bayer AG (Germany), Bristol-Myers Squibb company (US).


Regional Market Summary


Global Renal Cancer Drugs Market Share (%), by Region, 2017


Renal Cancer Drug Market Share


Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health


It is estimated that North America dominated the global renal cancer drugs market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. The American Cancer Society estimated about 22,660 women and 42,680 men new cases of kidney cancer in 2018 in the US This influences the market growth in North America.


Europe stood the second largest in the renal cancer drugs market owing to the increasing use of smoking and increasing tobacco usage. According to the World Health Organization’s (WHO) Fact Sheet on Tobacco and Oral Health (2018), Europe has the highest prevalence of smoking among adult population that is 28% of adults in Europe are engaged in smoking. Such a high prevalence of tobacco smoking in this region facilitates the market growth.


Asia-Pacific was projected to be the fastest growing region for the global renal cancer drugs market in 2017. The market is expected to witness growth owing to the rising prevalence of kidney cancer, changing lifestyle, and increasing tobacco use within the population. Such a high prevalence of oral cancer favors the market growth in this region. According to the National Center for Biotechnology Information, August 2016, report 121, 099 renal cancer cases were recorded in Asian countries in 2012, the number is expected to grow in coming years. This influences the market growth in this region.


The Middle East and Africa holds the least share in the global renal cancer drugs market due to the presence of poor health expenditure, low awareness, and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers


Market Segmentation and Key Market Players


Some of the key players in the global renal cancer drugs market are Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Genentech, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Cipla Limited (India), Active Biotech AB (Sweden), Amgen (US), Bayer AG (Germany), Bristol-Myers Squibb company (US).


Renal Cancer Drugs Market, by Therapeutic Class



  • Targeted Therapy

  • ImmunoTherapy


Renal Cancer Drugs Market, by Pharmacologic Class



  • Angiogenesis Inhibitors

  • mTOR Inhibitors

  • Monoclonal Antibodies

  • Cytokine Immunotherapy (IL-2)


Renal Cancer Drugs Market, by Type



  • Clear Cell

  • Papillary

  • Chromophobe

  • Oncocytic

  • Collecting Duct

  • Othes


Renal Cancer Drugs Market, by End-Users



  • Hospitals and clinics

  • Ambulatory surgical centers

  • Diagnostic centers

  • Research centers

  • Others


Renal Cancer Drugs Market, by Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: Significant Value
  CAGR   2022-2030: 5.50% CAGR
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Therapeutic class, Pharmacologic class, Type, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Genentech, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Cipla Limited (India), Active Biotech AB (Sweden), Amgen (US), Bayer AG (Germany), Bristol-Myers Squibb company (US).
  Key Market Opportunities

  • High cost of surgical procedures
  • Expensive chemotherapy treatments
  • The side effects and reaction associated with treatments
  •   Key Market Drivers   Increasing use of tobacco, smoking, and increasing alcohol consumption


    Speak to Analyst Ask for Customization